Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Ocul Surf. 2012 Jan 25;10(2):67–83. doi: 10.1016/j.jtos.2012.01.005

Table 3.

Summary of clinical trials investigating topical bevacizumab for the treatment of corneal NV

Author Corneal
Pathology		 N Conc. Treatment
Frequency		 Duration
(Days)		 Percent with
Decreased NV		 Percent with
Ocular Event
DeStafeno 4, 5 2 1.00% 4/day 25 100% 0%
Bock 1, 3 5 0.50% 5/day 108 100% 20%
Kim 1, 2, 3, 6, 9 10 1.25% 2/day 30-90 70% 60%
Dastjerdi 1, 2, 3, 6, 7, 8, 9 10 1.00% 4/day 21 100% 0%
Koenig 1, 2, 3, 6, 7, 8, 9, 10, 11 30 0.50% 5/day 102 80% 16.7%

Corneal pathology: 1) keratoplasty, 2) HSV keratitis, 3) chemical burn, 4) cicatricial pemphigoid, 5) traumatic rupture, 6) pterygium, 7) dry eye disease, 8) limbal stem cell deficiency, 9) Stevens-Johnson syndrome, 10) measles keratitis, 11) Salzmann’s nodular degeneration. (Conc. = Concentration).